Elisa Luño Fernández-rekin lankidetzan egindako argitalpenak (16)

2015

  1. Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: Results from the Spanish registry

    Leukemia, Vol. 29, Núm. 9, pp. 1875-1881

  2. Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: A population-based study

    The Lancet Haematology, Vol. 2, Núm. 6, pp. e260-e266

2014

  1. Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion

    British Journal of Haematology, Vol. 166, Núm. 2, pp. 189-201

  2. Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome

    Leukemia Research, Vol. 38, Núm. 5, pp. 551-556

  3. Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis

    Leukemia Research, Vol. 38, Núm. 3, pp. 304-309

2013

  1. Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome

    Journal of Clinical Oncology, Vol. 31, Núm. 7, pp. 916-922

2012

  1. Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome

    Cancer, Vol. 118, Núm. 1, pp. 127-133

  2. Prognostic value of trisomy 8 as a single anomaly and the influence of additional cytogenetic aberrations in primary myelodysplastic syndromes

    British Journal of Haematology, Vol. 159, Núm. 3, pp. 311-321

  3. The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome

    Leukemia Research, Vol. 36, Núm. 3, pp. 287-292

2011

  1. Clinical impact of the clone size in MDS cases with monosomy 7 or 7q deletion, trisomy 8, 20q deletion and loss of Y chromosome

    Leukemia Research, Vol. 35, Núm. 6, pp. 834-836

  2. Cytogenetic risk stratification in chronic myelomonocytic leukemia

    Haematologica, Vol. 96, Núm. 3, pp. 375-383

  3. Evaluation of tolerability and efficacy of imatinib mesylate in elderly patients with chronic phase CML: ELDERGLI study

    Leukemia Research, Vol. 35, Núm. 9, pp. 1184-1187

  4. Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome

    Cancer, Vol. 117, Núm. 24, pp. 5529-5537

2009

  1. C005 Prognostic impact of the proportion of aberrant metaphases in patients with a primary myelodysplastic syndrome

    Leukemia Research, Vol. 33, Núm. SUPPL. 1

  2. P029 Prognostic relevance of specific chromosomal abnormalities in chronic myelomonocytic leukemia

    Leukemia Research, Vol. 33, Núm. SUPPL. 1

  3. P030 Prognostic impact on survival of an unsuccessful conventional cytogenetic study in patients with myelodysplastic syndromes (MDS)

    Leukemia Research, Vol. 33, Núm. SUPPL. 1